Metformin Use in Chronic Kidney Disease: The CKD-Met Study

Civil Hospices of Lyon

Status: Unknown

Conditions: Chronic Kidney Disease; Type 2 Diabetes

Treatments: Other: modalities of metformin prescription

Study type: Observational

Funder types: Other

Identifiers

NCT02844153

69HCL16_0408

Details and patient eligibility

About

Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit.

Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients.

The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years old or more
• Type 2 diabetes
• Seen by a nephrologist (consultation or hospitalization) between March 2014 and March 2020 in the Department of Nephrology, Lyon Sud university hospital, France

Exclusion criteria

• On-going treatment by dialysis
• Kidney transplantation
• Type 1 diabetes
• Missing data (metformin treatment)

Trial design

1,000 participants in 1 patient group

6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)

Description:

All patients with type 2 diabetes seen for the first time by a nephrologist.

Treatment:

Other: modalities of metformin prescription